|4Jan 13, 5:28 PM ET

Clifton R. LaDuane 4

4 · KEMPHARM, INC · Filed Jan 13, 2023

Insider Transaction Report

Form 4
Period: 2023-01-13
Transactions
  • Purchase

    Common Stock

    2023-01-13$5.58/sh+25$1409,277 total
  • Purchase

    Common Stock

    2023-01-13$5.82/sh+610$3,5509,252 total

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4